New Drug May Help Keep Hodgkin Lymphoma at Bay

New Drug May Help Keep Hodgkin Lymphoma at Bay

New Drug May Help Keep Hodgkin Lymphoma at Bay

In study, brentuximab extended time patients survived without further progression of the blood cancer

SOURCES: Owen O'Connor, M.D., professor of medicine and experimental therapeutics, and director, Center for Lymphoid Malignancies, Columbia University Medical Center, New York City; Jonathan Kolitz, M.D., associate chief, hematologic oncology, North Shore-LIJ Cancer Institute, Lake Success, N.Y.; The Lancet, news release, March 18, 2015

WEDNESDAY, March 18, 2015 (HealthDay News) -- An FDA-approved drug doubled the amount of time that patients with Hodgkins lymphoma survived without any progression in their disease, a new study shows.

All of the patients also received stem cell therapy along with the drug, called brentuximab vedotin.

While the results are encouraging, doctors may never know if the drug is actually lengthening patients' lives, said Dr. Owen O'Connor, director of the Center for Lymphoid Malignancies at Columbia University Medical Center in New York City.

That's because brentuximab is fast becoming standard care for all patients with Hodgkin lymphoma who've relapsed after stem cell transplant, he said. So, a trial comparing the survival of patients who got the drug against those who did not might never be feasible, due to ethical concerns.

O'Connor was not involved in the trial, which was led by Dr. Craig Moskowitz, professor of medicine at Memorial Sloan Kettering Cancer Center in New York City. His team published the findings March 18 in The Lancet. The study was funded by Seattle Genetics Inc. and drug maker Takeda.

According to the American Cancer Society, about 9,000 new cases of Hodgkin lymphoma are diagnosed each year, and more than 1,100 people die from the illness annually. The cancer most often strikes young adults.

The phase 3 trial of brentuximab vedotin included 329 patients, aged 18 and older, who were at high risk of cancer relapse or progression after undergoing stem cell transplant, in which healthy stem cells from the patient are used to replace those lost to cancer or chemotherapy.

The patients were randomly assigned to receive 16 cycles of brentuximab vedotin infusions once every three weeks, or an inactive placebo.

After two years, there was no cancer progression in 65 percent of the patients who received the drug, compared with 45 percent of those in the placebo group, the researchers found. Progression-free survival was 43 months for those who received the drug, compared with 24 months for those in the placebo group.

"Nearly all of these patients who are progression-free at two years are likely to be cured since relapse two years after a transplant is unlikely," Moskowitz said in a journal news release. "No medication available today has had such dramatic results in patients with hard-to-treat Hodgkin lymphoma," he said.

O'Connor agreed. He said the new findings "represent a significant advance for patients with high-risk Hodgkin lymphoma who relapse or were [unresponsive] following initial therapy."

Common side effects associated with the drug were numbness or pain in the extremities due to nerve damage, and low white blood cell count.

As the researchers explained, brentuximab is an antibody that's attached to a chemotherapy drug that seeks out a protein on Hodgkin lymphoma cells. The drug then "sticks" to the protein and delivers targeted chemotherapy directly into the cancer cells, killing them.

Dr. Jonathan Kolitz is associate chief of hematologic oncology at North Shore-LIJ Cancer Institute in Lake Success, N.Y. He called brentuximab "a welcome addition to strategies aimed at improving outcomes in patients with Hodgkin lymphoma."

Brentuximab has been approved in 50 countries to treat patients with relapsed or treatment-resistant Hodgkin lymphoma, and received U.S Food and Drug Administration approval in 2011.

More information

The American Cancer Society has more about Hodgkin lymphoma.
Copyright © 2015 HealthDay. All rights reserved.